{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:27:50Z","timestamp":1790173670777,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T00:00:00Z","timestamp":1583884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T00:00:00Z","timestamp":1583884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Not applicable","award":["0"],"award-info":[{"award-number":["0"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00405-020-05891-2","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T09:04:33Z","timestamp":1583917473000},"page":"1273-1280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["CDK4\/6 inhibitors in P16\/HPV16-negative squamous cell carcinoma of the head and neck"],"prefix":"10.1007","volume":"277","author":[{"given":"Camelia","family":"Billard-Sandu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Gan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Paule","family":"Sablin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Dumitrescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Billard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,11]]},"reference":[{"key":"5891_CR1","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa0802656","journal-title":"N Engl J Med"},{"key":"5891_CR2","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394:1915\u20131928. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7","journal-title":"Lancet"},{"key":"5891_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Tourneau CL, Dinis J, Licitra L, Ahn M-J et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393:156\u2013167. https:\/\/doi.org\/10.1016\/S0140-6736(18)31999-8","journal-title":"Lancet"},{"key":"5891_CR4","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"key":"5891_CR5","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1126\/science.1208130","volume":"333","author":"N Stransky","year":"2011","unstructured":"Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A et al (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333:1157\u20131160. https:\/\/doi.org\/10.1126\/science.1208130","journal-title":"Science"},{"key":"5891_CR6","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature14129","volume":"517","author":"CGA Network","year":"2015","unstructured":"Network CGA (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576\u2013582. https:\/\/doi.org\/10.1038\/nature14129","journal-title":"Nature"},{"key":"5891_CR7","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1158\/1078-0432.CCR-07-1402","volume":"14","author":"WH Westra","year":"2008","unstructured":"Westra WH, Taube JM, Poeta ML, Begum S, Sidransky D, Koch WM (2008) Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res Off J Am Assoc Cancer Res 14:366\u2013369. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1402","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"5891_CR8","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.celrep.2014.05.012","volume":"7","author":"S Henderson","year":"2014","unstructured":"Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR (2014) APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 7:1833\u20131841. https:\/\/doi.org\/10.1016\/j.celrep.2014.05.012","journal-title":"Cell Rep"},{"key":"5891_CR9","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.ijrobp.2015.12.022","volume":"94","author":"JP Zevallos","year":"2016","unstructured":"Zevallos JP, Yim E, Brennan P, Liu AY, Taylor JM, Weissler M et al (2016) Molecular profile of human papillomavirus-positive oropharyngeal squamous cell carcinoma stratified by smoking status. Int J Radiat Oncol Biol Phys 94:864. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.12.022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5891_CR10","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","volume":"24","author":"GI Shapiro","year":"2006","unstructured":"Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770\u20131783. https:\/\/doi.org\/10.1200\/JCO.2005.03.7689","journal-title":"J Clin Oncol"},{"key":"5891_CR11","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1177\/1947601913478972","volume":"3","author":"SJ Baker","year":"2012","unstructured":"Baker SJ, Reddy EP (2012) CDK4: a key player in the cell cycle, development, and cancer. Genes Cancer 3:658\u2013669. https:\/\/doi.org\/10.1177\/1947601913478972","journal-title":"Genes Cancer"},{"key":"5891_CR12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.4161\/cc.9.4.10611","volume":"9","author":"S Paternot","year":"2010","unstructured":"Paternot S, Bockstaele L, Bisteau X, Kooken H, Coulonval K, Roger PP (2010) Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle Georget Tex 9:689\u2013699. https:\/\/doi.org\/10.4161\/cc.9.4.10611","journal-title":"Cell Cycle Georget Tex"},{"key":"5891_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2982","volume":"11","author":"CR Leemans","year":"2011","unstructured":"Leemans CR, Braakhuis BJM, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9\u201322. https:\/\/doi.org\/10.1038\/nrc2982","journal-title":"Nat Rev Cancer"},{"key":"5891_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1600-0714.2005.00343.x","volume":"34","author":"VB Wreesmann","year":"2005","unstructured":"Wreesmann VB, Singh B (2005) Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol 34:449\u2013459. https:\/\/doi.org\/10.1111\/j.1600-0714.2005.00343.x","journal-title":"J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol"},{"key":"5891_CR15","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1158\/2159-8290.CD-12-0537","volume":"3","author":"CR Pickering","year":"2013","unstructured":"Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM et al (2013) Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 3:770\u2013781. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0537","journal-title":"Cancer Discov"},{"key":"5891_CR16","doi-asserted-by":"publisher","first-page":"e26399","DOI":"10.1371\/journal.pone.0026399","volume":"6","author":"Z Feng","year":"2011","unstructured":"Feng Z, Guo W, Zhang C, Xu Q, Zhang P, Sun J et al (2011) CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. PLoS ONE 6:e26399. https:\/\/doi.org\/10.1371\/journal.pone.0026399","journal-title":"PLoS ONE"},{"key":"5891_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-T\u00e2n PF et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24\u201335. https:\/\/doi.org\/10.1056\/NEJMoa0912217","journal-title":"N Engl J Med"},{"key":"5891_CR18","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1038\/sj.onc.1205214","volume":"21","author":"T Wiest","year":"2002","unstructured":"Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX (2002) Involvement of intact HPV16 E6\/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21:1510\u20131517. https:\/\/doi.org\/10.1038\/sj.onc.1205214","journal-title":"Oncogene"},{"key":"5891_CR19","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E et al (2004) Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427\u20131438","journal-title":"Mol Cancer Ther"},{"key":"5891_CR20","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ et al (2009) PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res BCR 11:R77. https:\/\/doi.org\/10.1186\/bcr2419","journal-title":"Breast Cancer Res BCR"},{"key":"5891_CR21","doi-asserted-by":"publisher","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-06-1098","volume":"66","author":"LB Baughn","year":"2006","unstructured":"Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R et al (2006) A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4\/6. Cancer Res 66:7661\u20137667. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1098","journal-title":"Cancer Res"},{"key":"5891_CR22","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","volume":"18","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS et al (2012) Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res Off J Am Assoc Cancer Res 18:568\u2013576. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0509","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"5891_CR23","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1038\/bjc.2011.177","volume":"104","author":"GK Schwartz","year":"2011","unstructured":"Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD et al (2011) Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2\/1). Br J Cancer 104:1862\u20131868. https:\/\/doi.org\/10.1038\/bjc.2011.177","journal-title":"Br J Cancer"},{"key":"5891_CR24","doi-asserted-by":"publisher","first-page":"6173","DOI":"10.1158\/1078-0432.CCR-13-1675","volume":"19","author":"J Rader","year":"2013","unstructured":"Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D et al (2013) Dual CDK4\/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res Off J Am Assoc Cancer Res 19:6173\u20136182. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1675","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"5891_CR25","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-1248","volume":"22","author":"JR Infante","year":"2016","unstructured":"Infante JR, Cassier PA, Gerecitano JF, Witteveen PO, Chugh R, Ribrag V et al (2016) A phase I study of the cyclin-dependent kinase 4\/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res Off J Am Assoc Cancer Res 22:5696\u20135705. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1248","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"5891_CR26","unstructured":"Phase I study of ribociclib plus cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck|Annals of Oncology|Oxford Academic n.d. https:\/\/academic.oup.com\/annonc\/article\/27\/suppl_6\/1002P\/2799758. Accessed 18 Mar 2019"},{"key":"5891_CR27","doi-asserted-by":"publisher","first-page":"14803","DOI":"10.18632\/oncotarget.7543","volume":"7","author":"BM Ku","year":"2016","unstructured":"Ku BM, Yi SY, Koh J, Bae Y-H, Sun J-M, Lee S-H et al (2016) The CDK4\/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget 7:14803\u201314813. https:\/\/doi.org\/10.18632\/oncotarget.7543","journal-title":"Oncotarget"},{"key":"5891_CR28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","volume":"32","author":"LM Gelbert","year":"2014","unstructured":"Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ et al (2014) Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine. Invest New Drugs 32:825\u2013837. https:\/\/doi.org\/10.1007\/s10637-014-0120-7","journal-title":"Invest New Drugs"},{"key":"5891_CR29","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.4161\/cc.24091","volume":"12","author":"S Gogolin","year":"2013","unstructured":"Gogolin S, Ehemann V, Becker G, Brueckner LM, Dreidax D, Bannert S et al (2013) CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage. Cell Cycle Georget Tex 12:1091\u20131104. https:\/\/doi.org\/10.4161\/cc.24091","journal-title":"Cell Cycle Georget Tex"},{"key":"5891_CR30","doi-asserted-by":"publisher","first-page":"6512","DOI":"10.1863\/oncotarget.2270","volume":"5","author":"J Franco","year":"2014","unstructured":"Franco J, Witkiewicz AK, Knudsen ES (2014) CDK4\/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget 5:6512\u20136525. https:\/\/doi.org\/10.1863\/oncotarget.2270","journal-title":"Oncotarget"},{"key":"5891_CR31","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.4161\/cc.21127","volume":"11","author":"AK McClendon","year":"2012","unstructured":"McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E et al (2012) CDK4\/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle Georget Tex 11:2747\u20132755. https:\/\/doi.org\/10.4161\/cc.21127","journal-title":"Cell Cycle Georget Tex"},{"key":"5891_CR32","doi-asserted-by":"publisher","first-page":"9408","DOI":"10.1200\/JCO.2005.01.5594","volume":"23","author":"GK Schwartz","year":"2005","unstructured":"Schwartz GK, Shah MA (2005) Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol Off J Am Soc Clin Oncol 23:9408\u20139421. https:\/\/doi.org\/10.1200\/JCO.2005.01.5594","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5891_CR33","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1200\/jco.2014.32.15_suppl.527","volume":"32","author":"AS Clark","year":"2014","unstructured":"Clark AS, O\u2019Dwyer PJ, Heitjan D, Lal P, Feldman MD, Gallagher M et al (2014) A phase I trial of palbociclib and paclitaxel in metastatic breast cancer. J Clin Oncol 32:527\u2013527. https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.527","journal-title":"J Clin Oncol"},{"key":"5891_CR34","first-page":"747","volume":"33","author":"K Ogawa","year":"2013","unstructured":"Ogawa K, Yoshioka Y, Isohashi F, Seo Y, Yoshida K, Yamazaki H (2013) Radiotherapy targeting cancer stem cells: current views and future perspectives. Anticancer Res 33:747\u2013754","journal-title":"Anticancer Res"},{"key":"5891_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1747-1028-8-10","volume":"8","author":"KR Hagen","year":"2013","unstructured":"Hagen KR, Zeng X, Lee M-Y, Kahn ST, Pitner MKH, Zaky SS et al (2013) Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis. Cell Div 8:10. https:\/\/doi.org\/10.1186\/1747-1028-8-10","journal-title":"Cell Div"},{"key":"5891_CR36","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.bbrc.2012.10.119","volume":"430","author":"YK Han","year":"2013","unstructured":"Han YK, Lee JH, Park GY, Chun SH, Han JY, Kim SD et al (2013) A possible usage of a CDK4 inhibitor for breast cancer stem cell-targeted therapy. Biochem Biophys Res Commun 430:1329\u20131333. https:\/\/doi.org\/10.1016\/j.bbrc.2012.10.119","journal-title":"Biochem Biophys Res Commun"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-020-05891-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00405-020-05891-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-020-05891-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T09:37:39Z","timestamp":1666085859000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00405-020-05891-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,11]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["5891"],"URL":"https:\/\/doi.org\/10.1007\/s00405-020-05891-2","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,11]]},"assertion":[{"value":"2 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Camelia Billard-Sandu: travel fee: Merck Serono. Yun Gan Tao: travel fee: Merck Serono, MSD; advisory: MSD; research for Institution: MSD, Pfizer, Debiopharma. Marie-Paule Sablin: personal fees: Servier. Gabriela Dumitrescu: none declared. David Billard: none declared. Eric Deutsch: grants from Servier, BMS, MSD; grants and personal fees from Roche; Astrazeneca, Merck Serono, Boerhinger; personal fees from: Amgen, Accuray.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}